A phase I clinical trial using autologous, IL -7 gene -modified tumor cells in patients with disseminated melanoma has been recently completed. Although no major clinical responses were observed, increased antitumor cytotoxicity was measured in postvaccine peripheral blood lymphocytes in a subset of treated patients. To analyze the in situ immune response, the T cell receptor -chain variable region ( BV ) repertoire of T cells infiltrating postvaccine lesions was studied in two patients, and compared with that of T cells present in prevaccine ones, in peripheral blood lymphocytes, and, in one patient, in delayed type hypersensitivity ( DTH ) sites of autologous melanoma inoculum. A relative expansion of T cells expressing few BVs was observed in all postvaccine metastases, and their intratumoral presence was confirmed by immunohistochemistry. Length pattern analysis of the complementarity determining region 3 ( CDR3 ) indicated that the repertoire of T cells expressing some of these BVs was heterogeneous. At difference, CDR3, -chain joining region usage, and sequence analysis enabled us to demonstrate, within a T -cell subpopulation commonly expanded at DTH sites and at the postvaccine lesion of patient 1, that both DTH sites contained identical dominant T -cell clonotypes. One of them was also expressed at increased relative frequency in the postvaccine lesion compared to prevaccine specimens. These results provide evidence for immunological changes, including in situ clonally expanded T cells, in metastases of patients vaccinated with IL -7 gene -transduced cells.
T he recent identification of several melanoma -associated antigens that elicit systemic and local antitumor T-cell immune responses in melanoma patients has led to the development of various forms of active specific immunotherapy 1,2 such as peptide vaccination, 3 -6 dendritic cellbased therapy, 7 -9 or gene therapy. 10 -14 Although development of T-cell reactivity against autologous tumor cells could be detected by paired analysis of pre -and postvaccination peripheral blood lymphocytes (PBL ), clinical responses have been rarely observed. Few data are available on the effect of vaccination on T cells in the tumor tissue and on the nature of the elicited immune response in terms of T cell receptor (TCR ) diversity, specificity, and functional characteristics.
Information on this important issue might be obtained by analysis of TCR repertoire diversity through analysis of -chain variable region ( BV ) segments, complementarity determining region 3 ( CDR3 ) length, and TCR clonotype mapping -methods extensively used to demonstrate the presence, in a variety of tumor specimens, of in situ clonally expanded T cells. 15 -17 In several instances, once cultured in vitro, such clonally expanded tumor-infiltrating lymphocytes have been shown to display cytotoxic activity against the autologous tumor 18 -24 and have allowed the identification of the antigens that naturally elicited the in vivo antitumor immune response. 25 -28 Although fluorescent MHC class I/peptide tetrameric complexes containing antigenic peptides 29 have recently allowed enumeration of tumor antigen-specific CTL in a variety of clinical situations, 30 -32 usage of this powerful technique is still precluded when the allele /antigen combination that drives an immune response is unknown as it occurs in trials of vaccination with genetically modified autologous tumor cells.
Some of us recently reported that, in spite of the absence of clinical responses, vaccination with melanoma cells expressing IL -7 induced, in PBL of a subset of treated patients, an increased frequency of both MHC -restricted and -unrestricted tumor-reactive T lymphocytes. 13, 33, 34 The primary objective of this study was to analyse whether immunological changes occurred in the neoplastic lesions following vaccination and to measure the extent and the nature of such changes in comparison to blood and, for one of the patients, to delayed type hypersensitivity ( DTH ) skin reactions at sites of autologous tumor inoculum. Using semiquantitative polymerase chain reaction (PCR ) for BV repertoire and CDR3 length pattern analysis, we could demonstrate, in postvaccine metastases, increased frequency expression of polyclonal T-cell subsets characterised by few BVs. Immunohistochemistry confirmed infiltration of CD3 + CD8
+ T cells including those expressing the molecularly identified BVs. At difference with the polyclonal composition of the corresponding postvaccine lesion, both distinct available DTH skin sites displayed, within a T-cell subset studied in great detail, a highly skewed TCR repertoire, which included identical dominant T-cell clonotypes. One of these clonotypes was found at a 2 -fold higher frequency among transcripts infiltrating the postvaccine melanoma metastasis when compared to specimens obtained prior to vaccination.
Materials and methods

Patients and clinical protocol
The details of this vaccination trial, including method of vaccine production and part of immunological monitoring, have been previously described. 13 Briefly, metastatic melanoma patients were immunized by administering subcutaneously or intradermally 1Â10 6 up to 1.1Â10 7 autologous tumor cells transduced with the human IL -7 gene via ballistic transfer. 13 The total amount of IL-7 secreted by the vaccine ranged between 2 and 10 ng. Patients received three vaccinations at weekly intervals and a fourth vaccination during week sixth. Vaccination could then be continued at 4 -week intervals, depending upon clinical response. Two patients were analyzed in this study. Patient 1 was immunized starting from January 19, 1995. She received five vaccinations in total and the treatment ended in March 24 of the same year. She showed a stable disease, but died 4 months after the beginning of vaccination protocol. Patient 2 was immunized from December 12, 1995 to January 4, 1996. She received four vaccinations in total, had a mixed response, and survived for 10 months, showing an 8 -month stabilisation of disease, with skin metastases appearing and disappearing in short intervals of time. Patients 1 and 2 in our study correspond to patients 2 and 8, respectively, described in Möller et al. 13 Available specimens included preand postvaccine metastases, PBL, and, for patient 1, two DTH sites. No vaccination sites were available. DTH skin reactivity was performed using common recall antigens and mitomycin -inactivated, autologous melanoma cells and PBL as control ( each 4Â10 6 ) at the fourth vaccination. DTH sites are here defined as sites with autologous melanoma cells administered.
BV repertoire analysis
Total RNA from frozen sections of melanoma and DTH sites and from thawed cryopreserved PBL was prepared with the use of RNAzolB (Cinna /Biotecx, Friendswood, TX ). Single -stranded cDNA synthesis was carried out on 2 g of total RNA with oligo-dT and reverse transcriptase ( Superscript; Gibco BRL, Gaithersburg, MD ). After an ethanol precipitation, the cDNA was resuspended in 20 L of water. Semiquantitative reverse transcription ( RT ) PCR for BV repertoire analysis was performed as reported, 21 with the exception that amplifications were conducted according to the stepdown PCR parameters. 35, 36 Briefly, reaction mixtures consisted of 20 L containing 1 L of diluted cDNA, 200 M of each dNTP, 0.5 M of each primer, and 0.6 U of Ampli -Taq Gold ( Applied Biosystems, Norwalk, CT ). In order to normalize TCR cDNA among samples, cDNA, starting from a concentration corresponding to 100 ng of total RNA, was serially diluted and quantitated by amplification with oligonucleotide specific for the TCR -chain constant region (BC ). 21 After an initial preincubation at 948C for 3 minutes, cycling was divided into five groups consisting of an initial three -cycles group followed by four six -cycles groups with a denaturation step of 20 seconds at 948C and an elongation step of 1 minute at 728C. Annealing lasted for 40 seconds, started at temperatures of 648C in the first three -cycles group, and decreased by 38C in each of the later groups. Samples were subjected to a final incubation at 728C for 7 minutes. PCR products were electrophoresed on agarose gel, transferred to nylon membranes (Hybond N + ; Amersham International, Little Chalfont, UK ), hybridised with an internal 33 P-labeled BC oligonucleotide, and scanned with a PhosphorImager ( Molecular Dynamics, Sunnyvale, CA ). Individual bands were digitised and integrated with the use of the Imagequant software package provided by the manufacturer. The same amount of BC cDNA template for specimens of each patient was used for BV repertoire analysis performed with a panel of described oligonucleotide primers; 21, 37 amplification was performed as above with the exception that the last group of cycles consisted of nine, instead of six, cycles. The level of specific amplification was measured by densitometry following hybridization with a BC -specific probe as described above and each BV band was expressed as a percentage of the sum of all BV signals detected in the repertoire analysis. Designation of BV gene subfamilies is according to Arden et al. 38 
Immunohistochemical staining
Frozen sections (1 -2 m ) corresponding to the sections processed for mRNA extraction were placed on poly -Dlysine ( Sigma, St. Louis, MO )-coated slides, air-dried overnight at room temperature, and then fixed in acetone for 10 minutes. Acetone-fixed sections were treated with 0.3% H 2 O 2 in PBS /0.1% sodium azide for 1 hour to block the endogenous peroxidases, washed three times for 5 minutes in 39 After several brief rinses with PBS +Triton, tissue and cells were overlaid with a biotinylated goat anti -mouse Ig ( Dako ) or biotinylated goat antirat Ig (Vector Laboratories, Burlingame, CA ) at 1:100 dilution for 30 minutes and then, following additional washes (PBS + Triton ), the final incubation was done with streptavidin -conjugated horseradish -peroxidase (HRP Complex; Dako ) at 1:300 dilution for 30 minutes. Color was routinely developed using AEC ( 3-amino -9 -ethylcarbazole; Sigma ) for 10 minutes followed with a light hematoxylin counterstain for 1 minute ( Carazzi's hematoxylin ). The slides were mounted with glycerin gel.
CDR3 length pattern analysis
CDR3 length pattern analysis was performed using either BV-specific sense primers 37 paired to a fluorescent -labeled ( ABI Fluorophore Fam; Applied Biosystems ) antisense BC -specific primer ( 5
0 ) paired to a panel of BJ -specific antisense primers. 40 Amplifications were as described for BV repertoire analysis except that the Famlabeled primers were used at a 0.1 -M concentration. Following heat denaturation, amplification products were subjected to electrophoresis on 6% denaturing sequencing gel using an automated sequencer (ABI Prism 377 DNA Sequencer; Applied Biosystems ), in the presence of a fluorescent size marker ( Gene -Scan-500 TAMRA; Applied Biosystems), and analyzed by automatic fluorescence quantification and size determination using Gene -Scan Analysis software ( Applied Biosystems ). Fragment's length of individual bands was automatically determined by comparing their electrophoretic mobility in the gel with that of molecular size markers loaded in the same lane. CDR3 lengths are then calculated including the serine residue encoded by the 3 0 end of the BV gene families CAS motif up to, but not including, the phenylalanine residue of the conserved BJ region FGXGT motif. 41 Frequency expression of the different CDR3 lengths was determined by comparing individual band intensity to the combined intensity of a given BV -BC or BV -BJ combination. For BJ repertoire analysis, the intensities of the different peaks for each of the BV14 -BJ combinations were added and the percentage of each BJ segment calculated allowing intersample comparisons.
Cloning and sequencing of TCR transcripts
Amplification products were subcloned using the TOPO TA Cloning Kit for Sequencing ( Invitrogen, Carlsbad, CA ) and used to transform TOP10 One Shot competent cells ( Invitrogen ). Plasmid DNA from random clones was extracted using QIAprep Spin Miniprep kit (Qiagen, Crawley, UK ), sequenced using the ABI PRISM DyeDeoxy Terminator Cycle Sequencing kit (Applied Biosystems) and run on an ABI 377 DNA sequencing machine ( Applied Biosystems ).
Results
Modulation of BV repertoire of T cells upon vaccination
To define the immune response occurring in melanoma patients at tumor and DTH sites as well as in peripheral blood following administration of an IL -7 gene -modified autologous tumor cells vaccine, 13 semiquantitative PCR analysis of BV gene usage for the entire repertoire was performed on different specimens obtained from two of the treated patients. The number, characteristics, and codes of clinical specimens are shown in Table 1 . In patient 1, a total of seven specimens -including two different prevaccine metastases (TIL -0a and TIL -0b) taken at 7 -month interval, yDate of isolation of the different biological specimens. All melanoma specimens were metastases of dermal origin. HLA type of patient 1 was A11, A32; B7, B52; Cw5, Cw5; and of patient 2 was A2, A11; B22, B75; Cw1, Cw3; DR1, DR15.
zCD3-positive lymphocytes infiltrating the neoplastic tissue and the vaccine sites were identified by staining sections with anti-CD3 antibody and coded using the brisk/nonbrisk/absent classification. 39 NA: not available.
Cancer Gene Therapy TCRBV in lesions of vaccinated melanoma patients M Carsana et al and two different skin biopsies obtained at DTH sites 48 hours after mitomycin -inactivated autologous melanoma inoculum at week 6 of treatment (DTH -1 and DTH -2 ) -were studied in comparison to a single postvaccine tumor lesion ( TIL -1) and to pre -and postvaccine PBL. In patient 2, five specimens were tested: two different synchronous postvaccine metastases (TIL -1 and TIL -2) were compared to a prevaccine tumor lesion ( TIL -0 ) and PBL. All tumor lesions analyzed were dermal melanoma metastases. Table 2 shows the relative frequency expression of each BV in all the different samples with most of BV specificities present in each sample. The most skewed repertoire, with presence of less than 50% of the BV tested, was displayed by the T-cell infiltrate of both DTH sites (DTH -1, DTH -2; patient 1) and of one postvaccine lesion ( TIL -1, patient 2 ). Figure 1 graphically illustrates the BV regions, which were considered overexpressed in the absence of any therapeutic intervention, in prevaccine metastases because they exceeded prevaccine PBL values by 1.8 -fold, a threshold well above prevaccine PBL mean values + 2 SD. Prevaccine lesions of patient 1 displayed overexpression of five BVs: a 2 -fold increase of BV1 and BV3, a 3 -fold increase of BV4 and BV14, and a 5-fold increase of BV17 gene subfamily representation was observed. Levels of overexpressed BV were highly comparable in both asynchronous prevaccine specimens ( TIL -0a, TIL -0b) analyzed (Fig 1) . In patient 2, overexpression of six BV gene subfamilies ( BV2, BV4, BV17, BV20, BV21, BV22 ) was detectable in the single prevaccination metastases (TIL -0) compared to prevaccine PBL (PBL -0 ) with levels ranging from 2 -to 6 -fold increase in expansion (Fig 1) . In both patients, some of the BVs overexpressed before vaccination maintained similar levels of expression in postvaccine lesions (Table 2 ) . Intersample variation for BV4, BV21, and BV22 was observed when, as in patient 2, different lesions could be studied (Table 2 ). Figure 2 illustrates the BV regions which were overexpressed in postvaccine lesions and /or PBL compared to the corresponding prevaccine specimens, suggesting occurrence of either a local (patient 1: BV14; patient 2: BV1, BV3, BV5 ) or local plus systemic response to vaccination (patient 1: BV3, BV8; patient 2: BV20 ).
At difference of tumor lesions in which relative expression of single BV regions, either overexpressed or not, seldom exceeded 10%, TCR analysis of T cells at the two different DTH sites of patient 1 clearly indicated that five and four of the BV subfamilies present in DTH -1 and DTH -2, respectively, were not only expressed each at more than 10% relative frequency, but also accounted for more than 75% of the entire repertoire (Table 2 ). Among these, BV14 was the only BV gene subfamily whose expansion was shared among the postvaccine metastasis ( TIL -1 ) and both DTH sites of patient 1 where, depending on the site, it accounted for 16% and 14% of the entire repertoire (DTH -1 and DTH -2, respectively; Table 2 and Fig 2 ) .
In conclusion, as a result of vaccine administration, a local or a local plus systemic mobilisation of T cells appeared to take place in both patients. Furthermore, an oligoclonal BV repertoire could be evidenced at the available DTH reaction sites, sampled at 48 hours from autologous melanoma inoculum. 
Each BV determination, expressed as mean percentage of the sum of all BV signals, was repeated three times (SD < 15%). For specimens identification, see table 1. Values less than 1% are indicated as < 1.
Cancer Gene Therapy TCRBV in lesions of vaccinated melanoma patients M Carsana et al
Immunohistochemical staining for in situ BV expression
To see whether these results could be corroborated by histological evidence, the dermal tumor lesions resected before or after vaccination therapy and molecularly studied as described above were examined for T-cell infiltration adopting the brisk/nonbrisk /absent code for defining patterns of infiltrating T cells.
39
Using anti -CD3 mAb, a common pattern emerged: in prevaccine dermal lesions of both patients, CD3 + infiltrating T lymphocytes were either nonbrisk (i.e., present and infiltrating only one or few foci in tumor tissues ) or absent ( i.e., present in the periphery but not infiltrating tumor tissues ) (Fig 3A, patient 1 and Fig 4A, patient 2 ) . Following vaccination, CD3 + T lymphocytes were seen in all lesions and could be classified as brisk (i.e., present throughout the entire lesion and interspersed among tumor tissues ) for patient 1 (Fig 3B ) or nonbrisk for patient 2 (Fig 4B ) . Most of CD3 + T lymphocytes were also stained by anti -CD8 mAb (Figs 3 and 4) . To further explore the nature of the immune response elicited at the tumor sites, we investigated, using mAbs directed to a number of BV regions, the lymphocytic infiltrate for the presence of T cells expressing the BV gene families found to be overexpressed by BV analysis. Staining of frozen sections corresponding to the molecularly analyzed sections indicated that T cells expressing BV 8 and BV14 ( patient 1 ) or BV 1 ( patient 2 ) were detectable in the postvaccination intratumoral T-cell infiltrate but not in the prevaccine one ( Figs 3B and 4B ) .
These data correlated with the above semiquantitative BV repertoire analysis and indicated that a CD3 + CD8 + infiltration of T cells, including those expressing the molecularly identified BV regions, occurred following vaccination in each postvaccine lesion.
CDR3 length pattern analysis
To directly assess repertoire complexity of T cells present at postvaccine tumor sites, CDR3 length pattern analysis was used. TCR -chain amplification products obtained by the use of primers for BV3 and BV14 ( patient 1 ) or BV1 ( patient 2), and some of the BV gene families expanded in the postvaccine lesions, in conjunction with a constant region (BC ) fluorophore -labeled primer, were separated on an automated sequencer. Amplifications of BV2 -expressing transcripts, present at high frequency in all samples of patient 2, were also included as control. The results are depicted by the histograms in Figure 5 , where each bar corresponds to percent frequency expression of the different CDR3 lengths, calculated as described in Materials and Methods, for each BV -BC PCR product. In both patients, for each BV analyzed, prevaccine PBL displayed almost exclusively a Gaussian -like size distribution of CDR3 intensity and a ladder pattern of 3 -bp spaced Figure 1 Summary of BV gene family overexpression in prevaccine melanoma metastases compared to prevaccine PBL of each patient. For each specimen, the entire repertoire analysis was performed (see Table 2 ), but only overexpressed BV gene families are shown (i.e., increased more than 1.8-fold over prevaccine PBL). Each BV determination, expressed as a mean percentage of the sum of all BV signals, was repeated three times. The results are presented as a mean percentage ( ± SD). For specimen identification, see Table 1 .
Cancer Gene Therapy TCRBV in lesions of vaccinated melanoma patients M Carsana et al bands of different length centered around 9 -10 amino acids. This distribution is expected for a normal, polyclonal repertoire. Postvaccine PBL profiles were either superimposable (BV3, patient 1; BV1 and BV2, patient 2) or displayed modifications in relative peak intensities. Comparison of CDR3 profiles displayed by T cells present in postvaccine tumor lesions to that present in prevaccine specimens and /or PBL ruled out the accumulation, at high frequency, of recurrent size transcripts. In patient 2, the postvaccine metastases displayed, for each of the two considered BVs, either overexpressed (BV1 ) or not ( BV2 ), a pattern more heterogeneous than the one observed in the corresponding prevaccine TIL whose CDR3 size profile contained only two dominant peaks. This recruitment of T cells with novel specificities in the postvaccine lesion of patient 2 is consistent with the quantitative and qualitative evaluation of the pre -and postvaccine intratumoral infiltrate displayed in Figure 4 .
Both distinct DTH vaccination sites from patient 1 had a skewed repertoire displaying, within T cells expressing BV14, only three dominant peaks, associated with CDR3 size of either 10, 12, or 13 amino acids in length. In DTH -1, 80% of all BV14 expressed a CDR3 rearrangement of 13 amino acids in size.
Identification of recurrent TCRB transcripts
Presence of an oligoclonal response, which included BV14 -positive T-cell populations of identical CDR3 length at both distinct DTH sites of patient 1, enabled us to test, first, whether this skewed TCR repertoire was due to clonally expanded T cells, and, second, whether T cells sharing identical TCR -chain rearrangements could be detected among the heterogeneous specificities present at tumor sites.
In order to address these questions, -chain joining region ( BJ ) usage for BV14 T cells present in each of the different specimens of patient 1 was determined. More than 90% of BV14 T cells present at DTH sites and in prevaccine lesions had their variable region joined to not more than three BJ segments, i.e., BJ1S5, BJ2S3, or BJ2S7, whereas BJ usage was heterogeneous in all other specimens studied ( data not shown ). The complexity of BV14 -BJ rearrangements was further dissected for all specimens by CDR3 size analysis leading to the finding that, with the exception of prevaccine Figure 2 Summary of overexpressed BV gene families in postvaccine lesions compared to corresponding prevaccine samples. For each specimen, the entire repertoire analysis was performed (see Table 2 ), but only overexpressed BV gene families are shown (i.e., increased more than 1.8-fold over prevaccine PBL and lesion/s). Each BV determination, expressed as a mean percentage of the sum of all BV signals, was repeated three times. The results are presented as a mean percentage ( ± SD). For specimen identification, see Table 1 .
Cancer Gene Therapy TCRBV in lesions of vaccinated melanoma patients M Carsana et al Figure 3 Immunohistochemical analysis of neoplastic lesions from patient 1. Consecutive frozen sections of a pre-(TIL-0a) (A) and of the postvaccine lesion (B) were subjected to histological examination and immunohistochemical staining with anti-CD3, anti-CD8, and anti-BV mAbs.
Original magnification was Â250, except for BV8 in the postvaccine lesion and BV14 in both lesions that were Â400.
Cancer Gene Therapy TCRBV in lesions of vaccinated melanoma patients M Carsana et al PBL, in the other specimens, J1S5 and J2S3 were uniquely used in rearrangements associated with 12 and 13 aminoacids -long CDR3 sizes. J2S7 was associated with a unique 10 -amino-acids -long CDR3 size in DTH -2 and TIL -0b and with 10 and 12 amino -acids -long CDR3 sizes in DTH -1, TIL -1, and TIL -0a (data not shown ).
To test the monoclonality of BV14 -BJ TCR rearrangements resolving in single peaks, BV14J2S3 amplification products from both DTH vaccination sites, which resolved in a 13 -amino-acids -long CDR3, were subcloned into a bacterial host and plasmid DNA was sequenced. All plasmids were found to share identical BV14 -SLSPVAGSTDTQY-J2S3 clonal rearrangements. This transcript also accounted for 80% (prevaccine PBL ), 90% ( postvaccine PBL ), and 100% (pre -and postvaccine TIL ) of all BV14J2S3 transcripts sequenced from the other specimens. Usage of J2S3 within BV14 T cells present in those specimens, assessed by -chain joining region usage in BV14 T cells (data not Figure 4 Immunohistochemical analysis of neoplastic lesions from patient 2. Consecutive frozen sections of the pre-(A) and of a postvaccine lesion (TIL-2) (B) were subjected to histological examination and immunohistochemical staining with anti-CD3, anti-CD8, and anti-BV1 mAbs.
Original magnification was Â250 except for CD3 and CD8 in the prevaccine lesion and for BV1 in both lesions that were Â400.
Cancer Gene Therapy TCRBV in lesions of vaccinated melanoma patients M Carsana et al shown), was heterogeneous and ranged from 63% and 41% ( DTH -1 and PBL -1 ) to 19%, 24%, 27%, and 28% in, respectively, TIL -1, TIL -0a , TIL -0b, and DTH -2 to 8% in PBL -0. Since also usage of BV14 within total T cells occurred at different frequencies among the different specimens (Table 2 ), we could estimate that relative frequency expression of this -chain accounted, in DTH sites, for, respectively, 4% (DTH -1) and 10% ( DTH -2 ) of total T-cell transcripts, whereas in pre -and postvaccine PBL for less than 0.06% and 0.4%. The same rearrangement, accounting for 1.5% of total T-cell transcripts in postvaccine lesion, displayed, if compared to both prevaccine lesions ( 0.7% TIL -0a and 0.8% TIL-0b ), a 2 -fold amplification.
Discussion
To clarify which mechanisms underlie therapeutic failure versus tumor eradication, the features of the immune response need to be studied directly in the neoplastic lesions where tumor /host interactions takes place. In a previous report, it was shown that vaccination with autologous melanoma cells transfected ex vivo to produce IL -7 induced, in PBL of the treated patients, both MHC-restricted as well as MHC -unrestricted lytic activity against the autologous melanoma. 13, 33, 34 In addition, a number of clones with antitumor specificity could be derived from PBL of one of the patients. 33 In spite of documentation of this antitumor Tcell response, no durable clinical responses were, however, observed. 13 Ex vivo sensitisation of pre -and postvaccine PBLs that identify a vaccine-specific systemic T cell response to immunisation is, however, not an unusual finding even in the absence of clinical responses.
In order to monitor whether a T-cell response could be detected directly in the neoplastic lesions, BV repertoire analysis was used in the present study to characterize the diversity of T cells infiltrating postvaccine dermal metastases of two of the vaccinated patients. In comparison with prevaccine specimens, all the postvaccine lesions studied displayed increased relative expression of few selected BV gene subfamilies. Similar BV profiles were found on different postvaccine specimens taken at different times from the same patient, indicating presence of few identical BV regions at increased frequency at multiple sites.
Immunohistochemical analysis performed on frozen sections corresponding to the ones examined in RT-PCR documented infiltrates of CD3 + CD8 + T lymphocytes. As already reported by some of us, 39 assessment of BV repertoire expression through immunohistochemistry might underestimate the effective frequency of T cells expressing the BV region recognized by a given mAb. Nonetheless, small subsets of T lymphocytes expressing each of the expanded BV gene family tested were identified within the frozen section taken from postvaccine but not prevaccine metastases. BV repertoire and CDR3 size analysis are, beside immunohistochemical staining, the only available methodology to follow the evolution of the immune response when whole autologous tumor cells are used for vaccination and when biopsies are not available for functional studies. BV clonal expansions identified by means of these techniques in primary and metastatic melanomas of untreated or vaccinated patients or in mixed lymphocyte -tumor cell cultures in vitro could be demonstrated to be driven by recognition of tumor antigens in a number of cases. 18 -28,42 -43 Using these techniques, a highly skewed TCR repertoire which included dominant CDR3 length transcripts could only be clearly documented, at least for the BV region studied, at both available DTH sites. Conversely, similarly performed CDR3 length pattern analysis did not reveal predominant transcripts in postvaccine metastasis when compared to prevaccine specimens and /or PBL. However, search of the clonal rearrangement which characterized one of the dominant transcripts at DTH sizes allowed us to demonstrate that this clonotype was already present, although at low frequency, among the heterogeneous tumor infiltrate of both prior vaccination lesions ( 0.7 -0.8% of total T-cell transcripts ) and displayed a 2 -fold amplification (1.5% of total T-cell transcripts ) in the postvaccine one. Given the conserved BJ usage in TCR transcripts of identical CDR3 lengths in the different specimens and the monoclonal origin of a second dominant clonotype using BJ1S5 at both DTH sites ( data not shown), sharing of other clonotypes at different frequency among these specimens is highly possible. These findings are in accordance with other studies that reported T-cell clonality at DTH sites following autologous tumor cell sensitization as well as sharing of identical clones among vaccine and metastatic melanoma sites. 22,44 -46 In conclusion, although the antitumor specificity of T cells present in postvaccine lesions and DTH sites as well as of the dominant TCR clonotypes could not be assessed, combined usage of molecular and immunohistochemical techniques has documented the occurrence of immunological changes in the intratumoral infiltrate of post -therapy lesions taken from two patients administered with a vaccine composed by autologous melanoma cells engineered to produce IL-7. Despite these observations, the extent of such modifications was incapable to constrain tumor growth. Further studies are necessary to establish whether distinguishing features ( qualitative /quantitative ) of the in situ Tcell infiltrate can be defined, which associate with achievement or, conversely, lack of achievement, of a clinical response in lesions of patient that differently respond to a therapeutic regimen.
